Orchestra BioMed Holdings annual revenue
2022
2023
2024
2025
Orchestra BioMed Holdings Revenue Growth & History (OBIO)
Orchestra BioMed Holdings reported $33.5M in revenue for fiscal 2025, an increase of 1169.22% from the previous fiscal year.
View full Orchestra BioMed Holdings company overviewOrchestra BioMed Holdings annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $33.5M | $30.8M | +1169.22% |
| 2024 | 2024-12-31 | $2.6M | −$122,000 | −4.42% |
| 2023 | 2023-12-31 | $2.8M | −$773,000 | −21.88% |
| 2022 | 2022-12-31 | $3.5M | — | — |
Orchestra BioMed Holdings quarterly revenue
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $88,000 | −$748,000 | −89.47% |
| Q1 2026 | 2026-03-31 | $110,000 | −$758,000 | −87.33% |
| Q4 2025 | 2025-12-31 | $30.9M | $30.7M | +12120.16% |
| Q3 2025 | 2025-09-30 | $861,000 | −$126,000 | −12.77% |
| Q2 2025 | 2025-06-30 | $836,000 | $58,000 | +7.46% |
| Q1 2025 | 2025-03-31 | $868,000 | $248,000 | +40.00% |
| Q4 2024 | 2024-12-31 | $253,000 | −$9,000 | −3.44% |
| Q3 2024 | 2024-09-30 | $987,000 | $568,000 | +135.56% |
| Q2 2024 | 2024-06-30 | $778,000 | −$137,000 | −14.97% |
| Q1 2024 | 2024-03-31 | $620,000 | −$544,000 | −46.74% |
| Q4 2023 | 2023-12-31 | $262,000 | −$841,000 | −76.25% |
| Q3 2023 | 2023-09-30 | $419,000 | −$744,000 | −63.97% |
| Q2 2023 | 2023-06-30 | $915,000 | $514,000 | +128.18% |
| Q1 2023 | 2023-03-31 | $1.2M | $298,000 | +34.41% |
| Q4 2022 | 2022-12-31 | $1.1M | — | — |
| Q3 2022 | 2022-09-30 | $1.2M | — | — |
| Q2 2022 | 2022-06-30 | $401,000 | — | — |
| Q1 2022 | 2022-03-31 | $866,000 | — | — |
Orchestra BioMed Holdings revenue growth trends
Orchestra BioMed Holdings's latest reported quarter, Q2 2026, generated $88,000 in revenue, a decrease of 89.47% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Orchestra BioMed Holdings source filings ↗